FEIBA NF 650 UNIT
ANTI-INHIBITOR COAGULANT COMPLEX : 650 UNIT · DIN 02480549 · TAKEDA CANADA INC
Health Canada status: CANCELLED PRE MARKET
What is FEIBA NF?
FEIBA NF 650 UNIT contains ANTI-INHIBITOR COAGULANT COMPLEX : 650 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02480549, held by TAKEDA CANADA INC, supplied as POWDER FOR SOLUTION ; KIT for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 09-Aug-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02480549 |
|---|---|
| Brand name | FEIBA NF |
| Generic / active ingredient | ANTI-INHIBITOR COAGULANT COMPLEX : 650 UNIT |
| Manufacturer | TAKEDA CANADA INC |
| Strength | 650 UNIT |
| Dosage form | POWDER FOR SOLUTION ; KIT |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B02BD03 FACTOR VIII INHIBITOR BYPASSING ACTIVITY |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 09-Aug-2023 |
What can be used instead?
Other Canadian products sharing ATC code B02BD03 FACTOR VIII INHIBITOR BYPASSING ACTIVITY. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FEIBA NF | 1300 UNIT | KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02202581 |
| FEIBA NF | 3250 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02353903 |
| FEIBA NF | 650 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | APPROVED | DIN 02489600 |
| FEIBA VH IMMUNO ANTI INHIBITOR | POWDER FOR SOLUTION | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | CANCELLED POST MARKET | DIN 00609137 |
Who else supplies FACTOR VIII INHIBITOR BYPASSING ACTIVITY worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FACTOR VIII INHIBITOR BYPASSING ACTIVITY appears in 714 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.